April 26th 2024
Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.
Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.
June 5th 2023
Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.
May 29th 2023
Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.
Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.
May 22nd 2023
Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.
A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.
May 15th 2023
Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.
Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.
May 8th 2023
Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.
Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.
May 1st 2023
A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.
Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.
April 24th 2023
Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.
Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.
April 15th 2022
Perspectives on the use of lenvatinib therapy to manage a patient with radioiodine-refractory DTC, preceding broader considerations for sequencing kinase inhibitor therapy.
Expert Marcia Brose, MD, details a clinical scenario wherein a patient is diagnosed with differentiated thyroid cancer and managed with surgical and radiotherapy.
February 13th 2015
Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses lenvatinib as a new treatment option for patients with radioactive iodine-refractory differentiated thyroid cancer.
November 2nd 2014
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.
January 24th 2014
Marcia S. Brose, MD, PhD, from the University of Pennsylvania, discusses the treatment of anaplastic thyroid cancer (ATC) and the FACT2 study.